Recent advances in the use of antigen-specific T cells for the treatment of cancer

Update on cancer therapeutics Pub Date : 2006-09-01 DOI:10.1016/j.uct.2006.06.002

Cassian Yee , Herschel Wallen , Naomi Hunder , John A. Thompson , David Byrd , J. Zachary Reilly , Deborah Hendricks , Karla Kenyon , Lisa Schirmer

{"title":"Recent advances in the use of antigen-specific T cells for the treatment of cancer","authors":"Cassian Yee , Herschel Wallen , Naomi Hunder , John A. Thompson , David Byrd , J. Zachary Reilly , Deborah Hendricks , Karla Kenyon , Lisa Schirmer","doi":"10.1016/j.uct.2006.06.002","DOIUrl":null,"url":null,"abstract":"<div><p><span>In recent years, the feasibility of isolating and expanding antigen-specific T cells for use in clinical trials has been established by several laboratories. The fundamental considerations associated with isolation or enrichment of antigen-specific effector cells in vitro, and the selection, expansion and administration of cellular products with the degree of rigor necessary for clinical trials have been addressed. These can now serve as a springboard for developing strategies that focus on enhancing the survival and function of adoptively transferred T cells. An increased understanding of cellular immunity, and the availability of advanced technologies to generate and monitor antigen-specific T cells, allows investigators to manipulate the immune response to an extent not previously possible. In this review, we describe recent discoveries that contribute to translational strategies in adoptive </span>T cell therapy.</p></div>","PeriodicalId":87487,"journal":{"name":"Update on cancer therapeutics","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2006-09-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.uct.2006.06.002","citationCount":"3","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Update on cancer therapeutics","FirstCategoryId":"1085","ListUrlMain":"https://www.sciencedirect.com/science/article/pii/S1872115X06000259","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}

引用次数: 3

Abstract

In recent years, the feasibility of isolating and expanding antigen-specific T cells for use in clinical trials has been established by several laboratories. The fundamental considerations associated with isolation or enrichment of antigen-specific effector cells in vitro, and the selection, expansion and administration of cellular products with the degree of rigor necessary for clinical trials have been addressed. These can now serve as a springboard for developing strategies that focus on enhancing the survival and function of adoptively transferred T cells. An increased understanding of cellular immunity, and the availability of advanced technologies to generate and monitor antigen-specific T cells, allows investigators to manipulate the immune response to an extent not previously possible. In this review, we describe recent discoveries that contribute to translational strategies in adoptive T cell therapy.

查看原文

微信好友朋友圈 QQ好友复制链接

本刊更多论文

利用抗原特异性T细胞治疗癌症的最新进展

近年来，一些实验室已经建立了分离和扩增抗原特异性T细胞用于临床试验的可行性。与体外抗原特异性效应细胞的分离或富集以及临床试验所需的严格程度的细胞产物的选择、扩增和给药相关的基本考虑已得到解决。这些现在可以作为开发策略的跳板，重点是提高过继性转移T细胞的存活和功能。对细胞免疫的进一步了解，以及产生和监测抗原特异性T细胞的先进技术的可用性，使研究人员能够在以前不可能的程度上操纵免疫反应。在这篇综述中，我们描述了有助于过继性T细胞治疗的翻译策略的最新发现。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文去求助

来源期刊

Update on cancer therapeutics

自引率

0.00%

发文量

期刊最新文献

Editorial Board TROG 96.01: TTBF and PSAdt as surrogates for disease specific mortality Anti-angiogenesis approach to genitourinary cancer treatment COX-2 inhibitors and colorectal cancer: The end or just a new beginning Immunomodulatory agents in oncology